Conference abstractPublished 21 Mar 2019
Exploratory process development of a second generation beta-amyloid cleaving enzyme inhibitor
Pfizer Inc.-Groton, USA
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Alzheimer’s disease (AD) is widely believed to be related to the production and deposition of the beta-amyloid (Aβ). Thus, beta-amyloid cleaving enzyme (BACE1) inhibitors, that can reduce the production of the Aβ peptide, are promising candidates for the treatment of AD. Pfizer researchers discovered a potent, selective BACE1 inhibitor that displayed good safety, tolerability, and pharmacokinetics from early stage clinical trials. The compound also exhibited excellent brain penetration, and potent in vivo efficacy. The exploratory active pharmaceutical ingredient (API) support strategy and the process development will be discussed. In this presentation, the synthesis of the complex target molecule will encompass the greening of a chiral isoxazoline production, continuous flow chemistry of a critical heteroaryl bromide-metal exchange and telescoped heteroaryl anion addition, and the GMP endgame development in multiple clinical campaigns.
Subjects
ChemistryAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalOrganic Chemistry: Current Research
- SubjectChemistry
- BylineArticles whose byline prints “Bryan Li”

